Lung Cancer

Lung cancer is the leading cause of cancer-related deaths among men and women in the United States, despite being the second most commonly diagnosed cancer.

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses the development of biomarkers in the study of lung cancer.

Bristol-Myers Squibb and AstraZeneca have each announced separate delays in the development of PD-1 and CTLA-4 inhibitor combinations as first-line therapies for patients with advanced or metastatic non–small cell lung cancer.

Hossein Borghaei, DO, chief, Division of Thoracic Medical Oncology, director, Lung Cancer Risk Assessment, associate professor, Department of Hematology/Oncology, Fox Chase Cancer Center, discusses how physicians can help patients with lung cancer feel more comfortable reporting adverse events (AEs) associated with immunotherapy.

Roy S. Herbst, MD, PhD, ensign professor of Medicine, professor of Pharmacology, chief of Medical Oncology, associate director for Translational Research, Yale Cancer Center and Smilow Cancer Hospital, discusses combination therapies for patients with lung cancer.

Paul A. Bunn, Jr., MD, professor of Medicine, head of the Division of Medical Oncology at the University of Colorado, discusses combining immunotherapy with chemotherapy and targeted agents in lung cancer.

Alice T. Shaw, MD, PhD, Director of Thoracic Oncology, Massachusetts General Hospital, discusses alectinib as first-line therapy in the treatment of patients with lung cancer.

Lori C. Sakoda, PhD, research scientist at Kaiser Permanente Division of Research and affiliate investigator of the Division of Public Health Sciences at the Fred Hutchinson Cancer Research Center, discusses her study examining the pleiotropic associations of genetic risk variants for chronic obstructive pulmonary disease (COPD) with lung cancer risk.

Christian Diego Rolfo, MD, PhD, professor and unit coordinator at Antwerp University discusses the European perspective on precision medicine in lung cancer and the importance of clinical trials across different markets.

Immunotherapy is quickly becoming a mainstay in the frontline setting for the treatment of patients with metastatic non–small cell lung cancer.

The FDA has granted a priority review to a supplemental biologics license application for pembrolizumab in combination with pemetrexed plus carboplatin as a treatment for patients with metastatic or advanced non-squamous non–small cell lung cancer, regardless of PD-L1 expression and without EGFR or ALK mutations.

Roy Herbst, MD, PhD, discusses the next steps with pembrolizumab in NSCLC, PD-L1 testing, and managing increased toxicities with combination regimens.

Scott J. Swanson, MD, co-director of Minimally Invasive Surgery and chief surgical officer at Brigham and Women’s Hospital, professor of Surgery at Harvard Medical School, discusses surgical choices for patients with multifocal lung cancer.

Raphael Bueno, MD, chief, Division of Thoracic Surgery co-director, Brigham and Women’s Lung Center, vice chairman of Surgery for Cancer and Translational Research, professor at Harvard Medical School, discusses gene expression signatures for squamous cell lung carcinoma.

Farhad Kosari, PhD, assistant professor of Biochemistry and Molecular Biology, discusses anti-tumor immunity as a key determinant for small-cell lung cancer (SCLC) survivorship.

Raffit Hassan, MD, head of Thoracic and Solid Tumor Immunotherapy Section at the National Cancer Institute Center for Cancer Research discusses immunotherapy in malignant pleural mesothelioma.

Roy S. Herbst, MD, PhD, professor of Medicine, chief of Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital, discusses the impact that immunotherapy has had on the frontline treatment of patients with lung cancer.

Paul A. Bunn, Jr, MD, professor of Medicine in Medical Oncology and head of the Division of Medical Oncology at the University of Colorado, discusses the current role of precision medicine in lung cancer.

Nicolas Girard, MD, professor of Respiratory Medicine and Thoracic Oncology at the Claude Bernard University in Lyon, France, and senior attending physician in the Thoracic Oncology Service of the Hospices Civils de Lyon, discusses the optimal methods to maximize the outcomes of crizitonib (Xalkori) when used as a treatment for patients with non-small cell lung cancer (NSCLC).

Hatim Husain, MD, assistant professor of Hematology-Oncology at The University of California San Diego Moores Cancer Center, discusses his study on monitoring the emergence of EGFR T790M ctDNA in urine from EGFR-mutated NSCLC.

David Carbone, MD, PhD, director of the James Thoracic Center, and professor of Medicine at The Ohio State University Comprehensive Cancer Center, discusses the effectiveness of different therapies to treat patients with lung cancer.

Mark G. Kris, MD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses what the future holds for the development of immunotherapy and targeted therapy in the treatment of patients with lung cancer.